Shanghai Guosheng Haitong Equity Investment Fund Partnership Enterprise (Limited Partnership) completed the acquisition of 5.12% stake in Guiyang Xintian Pharmaceutical Co.,Ltd. from Guiyang Xintian Biotechnology Development Co., Ltd.
March 28, 2021
Share
Shanghai Guosheng Haitong Equity Investment Fund Partnership Enterprise (Limited Partnership) signed an agreement to acquire 5.12% stake in Guiyang Xintian Pharmaceutical Co.,Ltd. (SZSE:002873) from Guiyang Xintian Biotechnology Development Co., Ltd for CNY 83.8 million on March 16, 2021. Under the terms of consideration, Shanghai Guosheng Haitong Equity Investment Fund Partnership Enterprise (Limited Partnership) will acquire 6 million shares at CNY 13.9 per shares.
Shanghai Guosheng Haitong Equity Investment Fund Partnership Enterprise (Limited Partnership) completed the acquisition of 5.12% stake in Guiyang Xintian Pharmaceutical Co.,Ltd. (SZSE:002873) from Guiyang Xintian Biotechnology Development Co., Ltd on March 29, 2021. Post completion, Shanghai Guosheng Haitong Equity Investment Fund Partnership Enterprise holds 5.12% stake in Guiyang Xintian Pharmaceutical Co.,Ltd.
Guiyang Xintian Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research, development, production and sales of Chinese patent drugs. The Company manufactures its products in the forms of capsules, mixture, granules, syrup, gel and tablets. The Companyâs main products include Ningmitai Capsule, Kuntai Capsule, Kushen Gel and Xiaokucao Oral Liquid .The Company distributes its products in the domestic market.
Shanghai Guosheng Haitong Equity Investment Fund Partnership Enterprise (Limited Partnership) completed the acquisition of 5.12% stake in Guiyang Xintian Pharmaceutical Co.,Ltd. from Guiyang Xintian Biotechnology Development Co., Ltd.
GUIYANG XINTIAN PHARMACEUTICAL CO.,LTD. 
